These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26526790)

  • 1. miR-193b Modulates Resistance to Doxorubicin in Human Breast Cancer Cells by Downregulating MCL-1.
    Long J; Ji Z; Jiang K; Wang Z; Meng G
    Biomed Res Int; 2015; 2015():373574. PubMed ID: 26526790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
    Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z
    Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1.
    Gao M; Miao L; Liu M; Li C; Yu C; Yan H; Yin Y; Wang Y; Qi X; Ren J
    Oncotarget; 2016 Sep; 7(37):59714-59726. PubMed ID: 27487127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.
    Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM
    Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy.
    Yin W; Nie Y; Zhang Z; Xie L; He X
    Oncol Rep; 2015 Jul; 34(1):368-74. PubMed ID: 25997995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
    Sun FD; Wang PC; Luan RL; Zou SH; Du X
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer.
    Xie X; Hu Y; Xu L; Fu Y; Tu J; Zhao H; Zhang S; Hong R; Gu X
    Tumour Biol; 2015 Sep; 36(9):7185-94. PubMed ID: 25894378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miRNA expression patterns in chemoresistant breast cancer tissues.
    Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
    Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer.
    Zhang R; Li Y; Dong X; Peng L; Nie X
    Med Oncol; 2014 Dec; 31(12):347. PubMed ID: 25416050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
    Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1.
    He H; Tian W; Chen H; Deng Y
    Mol Med Rep; 2016 Feb; 13(2):1923-9. PubMed ID: 26718267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
    Li XF; Yan PJ; Shao ZM
    Oncogene; 2009 Nov; 28(44):3937-48. PubMed ID: 19701247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
    Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
    Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1.
    Ou Y; Zhai D; Wu N; Li X
    Gene; 2015 Nov; 572(1):116-122. PubMed ID: 26143754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27(kip1) expression.
    Wang DD; Li J; Sha HH; Chen X; Yang SJ; Shen HY; Zhong SL; Zhao JH; Tang JH
    Gene; 2016 Sep; 590(1):44-50. PubMed ID: 27282281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1.
    Li XJ; Ji MH; Zhong SL; Zha QB; Xu JJ; Zhao JH; Tang JH
    Arch Med Res; 2012 Oct; 43(7):514-21. PubMed ID: 23085450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells.
    Lin SR; Yeh HC; Wang WJ; Ke HL; Lin HH; Hsu WC; Chao SY; Hour TC; Wu WJ; Pu YS; Huang AM
    J Cell Biochem; 2017 Jun; 118(6):1563-1573. PubMed ID: 27918099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells.
    Fang Y; Shen H; Cao Y; Li H; Qin R; Chen Q; Long L; Zhu XL; Xie CJ; Xu WL
    Braz J Med Biol Res; 2014 Jan; 47(1):60-9. PubMed ID: 24519092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MORC4 is a novel breast cancer oncogene regulated by miR-193b-3p.
    Yang Z; Zhuang Q; Hu G; Geng S
    J Cell Biochem; 2019 Mar; 120(3):4634-4643. PubMed ID: 30320920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.